Kiromic BioPharma, Inc. (OTC PINK: KRBP) has made a significant announcement regarding its clinical initiatives. The company, a pioneer in the field of biotherapeutics, is utilizing its exclusive DIAMOND® artificial intelligence and data mining platform to develop innovative cell therapies, with a primary focus on immuno-oncology. Recently, Kiromic has entered into a clinical trial agreement with the well-regarded Beverly Hills Cancer Center (BHCC) to initiate its Deltacel-01 Phase 1 Study.

In this agreement, BHCC, a respected private cancer center based in Southern California, will serve as the primary clinical site for evaluating Deltacel™ (KB-GDT-01). This product, developed by Kiromic, is an allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy intended for patients with non-small cell lung cancer (NSCLC).

This collaboration between Kiromic BioPharma and BHCC underscores the mutual dedication of both organizations to advancing the fight against cancer through innovative therapeutic approaches. BHCC, a comprehensive facility, offers various services, including radiation oncology, an infusion center, diagnostic imaging capabilities (MRI, CT, PET/CT), and a diagnostic laboratory. The center also boasts a notable history of conducting clinical trials across various cancer types.

Beverly Hills Cancer Center and Assistant Clinical Professor at UCLA-David Geffen School of Medicine, expressed great enthusiasm for this groundbreaking clinical journey. He emphasized the importance of providing patients with access to state-of-the-art therapies and renewed hope in their battle against cancer. Dr. Gabayan commended Kiromic as an innovative and forward-thinking company, highlighting the potential of this new therapeutic approach to contribute to scientific progress and enhance the lives of cancer patients worldwide.

Kiromic, described the clinical trial agreement as a significant first step in the development of this critical treatment. BHCC, known for its high-quality clinical research and patient care, is an ideal location for a thorough evaluation of Kiromic's cell therapy candidate. The company is also actively working to collaborate with other prestigious clinical trial sites to expand the study's reach and impact, potentially involving up to four sites. Updates on the progress of the Deltacel-01 clinical study, including the activation of additional sites, will be provided as the trial advances.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 80% to 85% of all lung cancer cases. Lung cancer remains the leading cause of cancer-related deaths in the United States, responsible for about one in every five cancer deaths.

 

Source: businesswire.com

Report Abuse